Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 208 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Early Alzheimer's Disease Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

The Interactive Physical and Cognitive Exercise System

NCT03069391
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, MCI, Aging, Mild Cognitive Impairment, Neurocognitive Disorder, Cognitive Impairment, Cognitive Change
Interventions
physical exercise alone (PES) first, cognitive exercise alone (iCE) first, interactive Physical and Cognitive Exercise (iPACES™)
Behavioral · Device
Lead sponsor
Union College, New York
Other
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Schenectady, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

NCT04524351
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease
Interventions
Posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
45 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Stamford, Connecticut • DeLand, Florida • Hallandale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 7, 2026, 10:40 AM EDT
Not listed Not applicable Interventional

tDCS and Cognitive Training for Mild Cognitive Impairment and Alzheimer's Dementia

NCT04507815
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Active Transcranial Direct Current Stimulation (tDCS), Sham Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
60 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability

NCT02002819
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
levetiracetam
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 7, 2026, 10:40 AM EDT
Active, not recruiting No phase listed Observational

A Diagnostic Test for Dementia With Lewy Bodies

NCT05479552
View directory record Official record
Conditions
MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
Interventions
Syn-One Test
Diagnostic Test
Lead sponsor
CND Life Sciences
Other
Eligibility
50 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Scottsdale, Arizona • La Jolla, California • Englewood, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 7, 2026, 10:40 AM EDT
Not listed Phase 2 Interventional

Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease

NCT05122598
View directory record Official record
Conditions
Mild Cognitive Impairment, Early Alzheimer's Disease, Memory Impairment
Interventions
COT, Sham
Drug
Lead sponsor
Evon Medics LLC
Industry
Eligibility
55 Years to 95 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 7, 2026, 10:40 AM EDT
Completed No phase listed Observational

Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

NCT05364307
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Prescreener database
Other
Lead sponsor
Global Alzheimer's Platform Foundation
Other
Eligibility
50 Years to 90 Years
Enrollment
1,555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
San Diego, California • Santa Ana, California • Aventura, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 3 Interventional

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

NCT05894954
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Mild
Interventions
Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management
Dietary Supplement · Combination Product · Behavioral
Lead sponsor
Alzheimer's Prevention and Reversal Project, Inc.
Other
Eligibility
45 Years to 76 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Folsom, California • San Rafael, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 7, 2026, 10:40 AM EDT
Completed No phase listed Observational

Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis

NCT03431896
View directory record Official record
Conditions
Amyloidosis, Amyloid, Amyloid Neuropathies, Familial, Amyloid Cardiomyopathy, Amyloid - Primary, Transthyretin Amyloidosis, AL Amyloidosis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults

NCT01264614
View directory record Official record
Conditions
Cognitive Decline, Dementia, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Strengthening exercise
Behavioral
Lead sponsor
Union College, New York
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 7, 2026, 10:40 AM EDT
Recruiting Early Phase 1 Interventional

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314
View directory record Official record
Conditions
Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 7, 2026, 10:40 AM EDT
Recruiting Phase 2 Interventional

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

NCT07094516
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VHB937, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
22
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 7, 2026, 10:40 AM EDT
Enrolling by invitation No phase listed Observational

Integrating eSAGE With EHR Data Using Machine Learning for the Early Detection and Monitoring of Cognitive Impairment in Individuals

NCT06017505
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Mild Cognitive Impairment, Worried Well
Interventions
electronic self administered gerocognitive examination (eSAGE)
Diagnostic Test
Lead sponsor
Douglas Scharre
Other
Eligibility
50 Years and older
Enrollment
1,486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 7, 2026, 10:40 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain

NCT02875496
View directory record Official record
Conditions
Early Onset Alzheimer Disease, Mild Cognitive Impairment, Depression, Aging
Interventions
Not listed
Lead sponsor
ElMindA Ltd
Industry
Eligibility
50 Years to 85 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
The Villages, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study of PTI-125 in Healthy Volunteers

NCT03784300
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Alzheimer Disease
Interventions
50 mg PTI-125, 100 mg PTI-125, 200 mg PTI-125
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 7, 2026, 10:40 AM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

NCT03712787
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Tilavonemab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
57 Years to 88 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
32
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 2 Interventional

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

NCT05291234
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
ABBV-916, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
32
States / cities
Tucson, Arizona • Irvine, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 7, 2026, 10:40 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers

NCT05457998
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Flutemetamol F18 Injection, [18F]-RO6958948 Injection, [18F]-MK-6240 Injection
Diagnostic Test
Lead sponsor
Butler Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

NCT01227564
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg, Placebo- Phosphate buffered saline (PBS)
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
40
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 7, 2026, 10:40 AM EDT
Terminated No phase listed Observational

Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects

NCT01018927
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Administering three additional MRI images
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 7, 2026, 10:40 AM EDT
Recruiting Phase 2 Interventional

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

NCT07033494
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
MK-2214, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
36
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional

Nasal Protollin in Early Symptomatic Alzheimer's Disease

NCT07187141
View directory record Official record
Conditions
Alzheimer Disease (AD)
Interventions
Protollin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease

NCT04552795
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
3TC
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 7, 2026, 10:40 AM EDT
Not listed Phase 2 Interventional

A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease

NCT05607615
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Hydroxypropyl Beta Cyclodextrin, Placebo
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Brooksville, Florida • Winter Park, Florida • Marrero, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 7, 2026, 10:40 AM EDT